AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in cancer survivors
Number of subjects: 982
Study 28837404 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine initiation in general population
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in adolescent survivors (ages 13 to 17 years)
Number of subjects: 982
Study 28837404 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine initiation in adolescent peers (ages 13 to 17 years)
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in young adult survivors (ages 18 to 26 years)
Number of subjects: 982
Study 28837404 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine initiation in young adult peers (ages 18 to 26 years)
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - lack of provider recommendation
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - perceived lack of insurance coverage
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - male sex
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - endorsement of vaccine-related barriers
Number of subjects: 982
Study 28837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of noninitiation - younger age (9 to 12 years)
Number of subjects: 982
Study 28837405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity
Number of subjects: 27
Study 28837405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (central review)
Number of subjects: 27
Study 28837405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 27
Study 28837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic critical illness patients
Number of subjects: 135
Study 28837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed chronic critical illness
Number of subjects: 135
Study 28837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of chronic critical illness
Number of subjects: 135
Study 28837885 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537
Study 28837885 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study 28838044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with vitamin-K antagonists or non-VKA oral anticoagulants
Number of subjects: 84
Study 28838044 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 84
Study 28838044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral anticoagulation
Number of subjects: 84
Study 28838044 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI and SAVR (both interventions)
Number of subjects: 84
Study 28838044 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 84
Study 28838858 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cartilage thickness change (Y2→Y4)
Number of subjects: 777
Study 28838858 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceding cartilage thickness loss (cMFTC)
Number of subjects: 777
Study 28838886 — intervention group
Group type: EXPERIMENTAL
Intervention: iMOVE intervention with 10 telephone-based health coaching sessions, smartphone with data plan, supportive health tracking software, and a wearable step-counting device.
Number of subjects: 107
Study 28838886 — intervention group
Group type: EXPERIMENTAL
Intervention: iMOVE intervention
Number of subjects: 107
Study 28838886 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the 12-week physical activity program with weekly group sessions and an individualized, progressive, home-based exercise program.
Number of subjects: 107
Study 28838886 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 107
Study 28838993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 350
Study 28838993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk group (n=199)
Number of subjects: 350
Study 28838993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk group (n=68)
Number of subjects: 350
Study 28838993 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk group (n=42)
Number of subjects: 350
Study 28840039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with silicone oil endotamponade, performed in 93% of cases, simultaneous with phacoemulsification and IOL implantation in 86% of cases.
Number of subjects: 14
Study 28840096 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28840147 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg intramuscularly weekly for 8 weeks)
Number of subjects: 13
Study 28840147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline intramuscularly weekly for 8 weeks)
Number of subjects: 13
Study 28840147 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 13
Study 28840147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28840587 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical shirt-based electrocardiography (ECG) monitoring using the Nuubo® ECG (nECG) system
Number of subjects: 220
Study 28840775 — intervention group
Group type: COMPARATOR
Intervention: Perinatal Asphyxia (PA)
Number of subjects: 0
Study 28840775 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic-Ischaemic Encephalopathy (HIE)
Number of subjects: 0
Study 28840775 — intervention group
Group type: COMPARATOR
Intervention: Pathway analysis for HIE
Number of subjects: 0
Study 28840919 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits with remote PD specialists
Number of subjects: 277
Study 28841389 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 60
Study 28841389 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg once daily
Number of subjects: 60
Study 28841389 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib across doses
Number of subjects: 60
Study 28841495 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experience (ACE) score
Number of subjects: 457
Study 28841677 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT workshop
Number of subjects: 32
Study 28841677 — intervention group
Group type: EXPERIMENTAL
Intervention: Community activities delivered by trainees
Number of subjects: 32
Study 28841744 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-HTTRx (antisense oligonucleotide)
Number of subjects: 0
Study 28841824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 weeks
Number of subjects: 131
Study 28841909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DCF regimen (6 cycles)
Number of subjects: 66
Study 28841909 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DCF regimen (8 cycles)
Number of subjects: 66
Study 28841909 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and 5-fluorouracil (CF) regimen (standard option)
Number of subjects: 66
Study 28842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels >134ng/ml
Number of subjects: 96
Study 28842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels <73ng/ml
Number of subjects: 96
Study 28842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor treatment
Number of subjects: 96
Study 28842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels
Number of subjects: 96
Study 28842390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames (VR intervention)
Number of subjects: 19
Study 28842415 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (unpredictable shocks) during retrieval of altered images
Number of subjects: 0
Study 28842415 — intervention group
Group type: COMPARATOR
Intervention: Safety condition (no shocks) during retrieval of altered images
Number of subjects: 0
Study 28842415 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of altered items during threat
Number of subjects: 0
Study 28842973 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor
Number of subjects: 446
Study 28843382 — intervention group
Group type: EXPERIMENTAL
Intervention: Air infusion into saline during office hysteroscopy
Number of subjects: 0
Study 28843918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d (mean 6.2 mg/d) for up to 16 weeks
Number of subjects: 402
Study 28844037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral angulation technique (LAT)
Number of subjects: 25
Study 28844037 — intervention group
Group type: COMPARATOR
Intervention: Traditional angulation technique (TAT)
Number of subjects: 25
Study 28844356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertubation with lignocaine
Number of subjects: 37
Study 28844372 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/d orally
Number of subjects: 214
Study 28844410 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI-724 (10mg/m and 40mg/m)
Number of subjects: 14
Study 28844410 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI-724 (160mg/m)
Number of subjects: 14
Study 28844733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients received brief clinician advice, video doctor message, health education booklet, and follow-up coaching sessions.
Number of subjects: 65
Study 28844733 — intervention group
Group type: COMPARATOR
Intervention: Control patients received usual care and cancer screening information.
Number of subjects: 65
Study 28844733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients
Number of subjects: 65
Study 28845238 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Training (AT) for 40 hours
Number of subjects: 56
Study 28845238 — intervention group
Group type: COMPARATOR
Intervention: Computer Games (CG)
Number of subjects: 56
Study 28845238 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MMN in ESZ individuals
Number of subjects: 56
Study 28845238 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-Deviant MMN
Number of subjects: 56
Study 28845304 — intervention group
Group type: EXPERIMENTAL
Intervention: Double internal limiting membrane (ILM) insertion
Number of subjects: 9
Study 28845508 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 41
Study 28845608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight variability over 6-week period
Number of subjects: 183
Study 28845608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight variability over 12-week period
Number of subjects: 183
Study 28845608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight variability early in a weight loss program
Number of subjects: 183
Study 28845608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight variability over 6-month period in men
Number of subjects: 183
Study 28846559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) combined with daclatasvir with or without ribavirin (n = 10/n = 6)
Number of subjects: 29
Study 28846559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) combined with ledipasvir with or without ribavirin (n = 2/n = 11)
Number of subjects: 29
Study 28846801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid premenstrual dysphoric disorder (PMDD)
Number of subjects: 1099
Study 28846801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid PMDD
Number of subjects: 1099
Study 28846953 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 overexpression >350 copies after induction
Number of subjects: 255
Study 28846953 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 overexpression >150 copies pre allo-HCT
Number of subjects: 255
Study 28847194 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided microwave ablation (MWA)
Number of subjects: 32
Study 28847910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12
Study 28847911 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with HTN-LVH and low RI (n=15, 5.9%)
Number of subjects: 266
Study 28847911 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients with HTN-LVH and normal RI (n=50; 19.5%)
Number of subjects: 266
Study 28847911 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients without LVH (n=191; 74.6%)
Number of subjects: 266
Study 28847998 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (50-1200 mg, 800 mg in safety expansion) plus bortezomib and dexamethasone
Number of subjects: 66
Study 28848011 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir at 100 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with ritonavir.
Number of subjects: 0
Study 28848011 — intervention group
Group type: COMPARATOR
Intervention: Cobicistat at 150 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with cobicistat.
Number of subjects: 0
Study 28848465 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-Session Mindfulness-Based Intervention
Number of subjects: 0
Study 28848465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Session Mindfulness-Based Intervention
Number of subjects: 0
Study 28848465 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 28848654 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 163
Study 28848654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 28848667 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug (specific intervention not mentioned)
Number of subjects: 31
Study 28848672 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-139 (625 mg/m)
Number of subjects: 46
Study 28848672 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-139 (various doses: 20, 40, 80, 160, 320, 420, 500, 625, 780 mg/m)
Number of subjects: 46
Study 28848672 — intervention group
Group type: EXPERIMENTAL
Intervention: IT-139
Number of subjects: 46
Study 28848879 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-Daily Glycopyrrolate
Number of subjects: 0
Study 28848879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28848909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 proteinase inhibitor (A1PI)
Number of subjects: 320
Study 28848909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 28850430 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally orientated treatment for ACNES
Number of subjects: 50
Study 28851109 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 321
Study 28851109 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 321
Study 28851316 — intervention group
Group type: EXPERIMENTAL
Intervention: ParvOryx (native parvovirus H-1) administered intravenously and intratumorally
Number of subjects: 7
Study 28851348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Environment and Policy Assessment and Observation (EPAO)
Number of subjects: 61
Study 28851348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified EPAO
Number of subjects: 61
Study 28851380 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40L stimulation of lymph node cells
Number of subjects: 6
Study 28851380 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell ELISPOT
Number of subjects: 6
Study 28851380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybridomas generated from lymph node cells after CD40L-stimulation
Number of subjects: 6
Study 28851416 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 GEP profile
Number of subjects: 322
Study 28851416 — intervention group
Group type: COMPARATOR
Intervention: Class 2 GEP profile
Number of subjects: 322
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy IL-6 levels
Number of subjects: 159
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy D-dimer levels
Number of subjects: 159
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 159
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of comorbidities
Number of subjects: 159
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased physical function by ADL Scale
Number of subjects: 159
Study 28851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model including IL-6 and D-dimer
Number of subjects: 159
Study 28851423 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitor veliparib in combination with carboplatin (V-C)
Number of subjects: 116
Study 28851423 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone (Control)
Number of subjects: 116
Study 28851447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic mild cognitive impairment (aMCI)
Number of subjects: 2323
Study 28851447 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-amnestic mild cognitive impairment (naMCI)
Number of subjects: 2323
Study 28851447 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated subjective cognitive complaints (SCCs)
Number of subjects: 2323
Study 28851447 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2323
Study 28851447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 2323
Study 28851512 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa
Number of subjects: 43
Study 28851731 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive physiological assessment for coronary stenosis
Number of subjects: 115
Study 28851773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track care
Number of subjects: 1820
Study 28851773 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 1820
Study 28851774 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Together intervention
Number of subjects: 0
Study 28851781 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study design with document acquisition and abstraction and in-person interviews.
Number of subjects: 1000000
Study 28851978 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy assessed by changes in SOFA score from admission (T1) to 48 hours later (T2)
Number of subjects: 21
Study 28851978 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score at admission (T1)
Number of subjects: 21
Study 28851978 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score at 48 hours (T2)
Number of subjects: 21
Study 28852473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative reverse Trendelenburg positioning (RTP)
Number of subjects: 1500
Study 28852473 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-campaign 2015 cohort with increased RTP
Number of subjects: 1500
Study 28852473 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit-documented RTP during surgery in 2015
Number of subjects: 1500
Study 28853310 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 0
Study 28853988 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier household food availability
Number of subjects: 2520
Study 28853988 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher log supermarket spending
Number of subjects: 2520
Study 28853988 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier household food availability (females)
Number of subjects: 2520
Study 28853988 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater log supermarket spending (females)
Number of subjects: 2520
Study 28854543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine delivered i.v. by target-controlled infusion
Number of subjects: 18
Study 28854909 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.
Number of subjects: 68
Study 28855148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ivermectin treatment with antiepilepsy drugs (AEDs)
Number of subjects: 110
Study 28855148 — intervention group
Group type: COMPARATOR
Intervention: Delayed ivermectin treatment (after 4 months) with antiepilepsy drugs (AEDs)
Number of subjects: 110
Study 28855200 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) or Golimumab (GLM)
Number of subjects: 223
Study 28855902 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg with AS01
Number of subjects: 291
Study 28855902 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg with different Adjuvant Systems (AS)
Number of subjects: 291
Study 28856009 — intervention group
Group type: EXPERIMENTAL
Intervention: High water intake (1.0 to 1.5 L/day increase)
Number of subjects: 631
Study 28856009 — intervention group
Group type: COMPARATOR
Intervention: Usual water intake (control group)
Number of subjects: 631
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week washout (WO) group
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week washout (WO) group
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week washout (WO) group
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher T2 lesion volume (LV) at baseline
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster decline in natalizumab RO
Number of subjects: 142
Study 28856176 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer washout period
Number of subjects: 142
Study 28856631 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy and SPI-guided general anaesthesia (ESPI Group, N=37)
Number of subjects: 72
Study 28856631 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodynamic monitoring (STDR Group, N=35)
Number of subjects: 72